CN110128336A - A kind of preparation method of Aripiprazole - Google Patents
A kind of preparation method of Aripiprazole Download PDFInfo
- Publication number
- CN110128336A CN110128336A CN201910498357.XA CN201910498357A CN110128336A CN 110128336 A CN110128336 A CN 110128336A CN 201910498357 A CN201910498357 A CN 201910498357A CN 110128336 A CN110128336 A CN 110128336A
- Authority
- CN
- China
- Prior art keywords
- piperazine
- dichlorophenyl
- salt
- alcohol
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
Abstract
This application discloses a kind of preparation methods of Aripiprazole, comprising the following steps: 1- (2,3- dichlorophenyl) piperazine or its salt are dissolved in polar solvent, Isosorbide-5-Nitrae-dibromobutane, acid binding agent is added, is reacted under conditions of the first heating, first is cooling, and the first filtering obtains the first filtrate；First filtrate steams solvent, adds weak polar solvent crystallization, and the second filtering obtains the second filtrate, dry, obtains 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt；In absolute alcohol, 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt, 7- hydroxyl -3 is added, 4- dihydro-quinolone, alcohol alkali react under conditions of the second heating, and second is cooling, it is poured into ice water and disperses, third filtering, washing, recrystallization obtain Aripiprazole.Method provided by the present application, raw materials technology are easy to get, and route is brief, can get high-purity target product, with art methods ratio, optimize process conditions, reduce production cost, good product quality, high income is conducive to industrialized production.
Description
Technical field
This application involves pharmaceutical technology fields, more particularly to a kind of preparation method of Aripiprazole.
Background technique
Aripiprazole belongs to second generation antipsychotics, is developed within 1988 by Japanese Otsuka company, 2002 Nian Mei
State's Initial Public Offering.Compared with conventional medicament, Aripiprazole has many advantages, such as that good effect, adverse reaction is few.EP367141 is disclosed
The method for preparing Aripiprazole and its derivative compound, with 7- hydroxyl -3,4- dihydro-quinolone for starting material, with Isosorbide-5-Nitrae-two
Bromobutane addition reaction obtains intermediate product, then A Li piperazine is made in intermediate product and 1- (2,3- dichlorophenyl) piperazine condensation
Azoles.The intermediate product of route preparation contains more double addition impurity, and gained Aripiprazole need to be through repeated recrystallize purifying side
It can get the purity of pharmaceutical grade, process is tedious, and total recovery is low, is unfavorable for industrialized production.
Summary of the invention
In order to solve the above technical problems, it is an object of the present invention to provide a kind of preparation methods of Aripiprazole；Ah. of the present invention
The preparation method of vertical piperazine azoles improves reaction condition for unfavorable factor present in original preparation process, simplifies operating process,
Product quality is improved, production cost is reduced, is more advantageous to industrialized production.
Technical solution provided by the invention is as follows:
A kind of preparation method of Aripiprazole, comprising the following steps:
1- (2,3- dichlorophenyl) piperazine or its salt are dissolved in polar solvent, and Isosorbide-5-Nitrae-dibromobutane, acid binding agent is added, the
It is reacted under conditions of one heating, first is cooling, and the first filtering obtains the first filtrate；
First filtrate steams solvent, adds weak polar solvent crystallization, and the second filtering obtains the second filtrate, dry, obtains
1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt；
In absolute alcohol, 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt, 7- hydroxyl -3,4- dihydro quinoline promise is added
Ketone, alcohol alkali react under conditions of the second heating, and second is cooling, are poured into ice water and disperse, third filtering, washing, recrystallization,
Obtain Aripiprazole.
Preferably, 1- (2, the 3- dichlorophenyl) piperazine or its salt be specially 1- (2,3- dichlorophenyl) piperazine, 1- (2,
3- dichlorophenyl) piperazine hydrochloride, 1- (2,3- dichlorophenyl) piperazine sulfate, 1- (2,3- dichlorophenyl) piperazine acetate,
Any one in 1- (2,3- dichlorophenyl) piperazine hydrobromide.
Preferably, the polar solvent is specially one of methanol, normal propyl alcohol, n-butanol, the tert-butyl alcohol or a variety of；With/
Or,
The volumetric usage of the polar solvent is 3-20 times of 1- (2,3- dichlorophenyl) piperazine or the quality of its salt.
Preferably, the acid binding agent is specially potassium carbonate, saleratus, sodium carbonate, sodium bicarbonate, pyridine, triethylamine, N,
Any one or more in N- diisopropylethylamine.
Preferably, the temperature of first heating is 40-80 DEG C；And/or the time of first heating is 6-15h.
Preferably, the weak polar solvent is specially petroleum ether, n-hexane, pentane, hexamethylene, benzene,toluene,xylene
One of or it is a variety of；And/or
The volumetric usage of the weak polar solvent is 1-10 times of 1- (2,3- dichlorophenyl) piperazine or the quality of its salt.
Preferably, the absolute alcohol is specially one of methanol, ethyl alcohol, normal propyl alcohol, isopropanol, n-butanol, the tert-butyl alcohol
Or it is a variety of.
Preferably, the alcohol alkali be specially potassium methoxide, it is potassium ethoxide, potassium isopropoxide, potassium tert-butoxide, sodium methoxide, sodium ethoxide, different
Any one or more in sodium propoxide, sodium tert-butoxide；And/or
The dosage of the alcohol alkali is the 1-4 times of equivalent of 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt.
Preferably, the temperature of second heating is 40-80 DEG C；And/or the time of first heating is 2-8h.
Preferably, it is recrystallized using alcohol-water mixed solution.
The preparation method of Aripiprazole provided by the present application, by Isosorbide-5-Nitrae-dibromobutane elder generation and 1- (2,3- dichlorophenyl) piperazine
Or its reactant salt, 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt intermediate is made, then by 1- (2,3- dichlorophenyl) piperazine
Aripiprazole is made in piperazine azepine cyclopentamine salt intermediate and the dihydro-quinolone condensation reaction of 7- hydroxyl -3,4-.It is provided by the present application
Preparation method, raw materials technology are easy to get, and route is brief, can get high-purity target product, with art methods ratio, optimize work
Skill condition, reduces production cost, good product quality, and high income is conducive to industrialized production.
Detailed description of the invention
In order to illustrate the technical solutions in the embodiments of the present application or in the prior art more clearly, to embodiment or will show below
There is attached drawing needed in technical description to be briefly described, it should be apparent that, the accompanying drawings in the following description is only this
The some embodiments recorded in application, for those of ordinary skill in the art, without creative efforts,
It is also possible to obtain other drawings based on these drawings.
Fig. 1 is 1- (2,3- dichlorophenyl) piperazine ring butylamine salt intermediate of reacted preparation in the embodiment of the present invention 1
Chromatogram；
Fig. 2 is the chromatogram of the Aripiprazole of reacted preparation in the embodiment of the present invention 3；
Fig. 3 is the nuclear magnetic resonance spectroscopy of 1- (2,3- dichlorophenyl) piperazine ring butylamine salt in the embodiment of the present invention 1；
Fig. 4 is the nuclear magnetic resonance spectroscopy of Aripiprazole in the embodiment of the present invention 3.
Specific embodiment
In order to make those skilled in the art better understand the technical solutions in the application, below in conjunction with the application reality
The attached drawing in example is applied, the technical scheme in the embodiment of the application is clearly and completely described, it is clear that described implementation
Example is merely a part but not all of the embodiments of the present application.Based on the embodiment in the application, this field is common
The application protection all should belong in technical staff's every other embodiment obtained without making creative work
Range.
Please be as shown in Figures 1 to 4, the embodiment of the present invention provides a kind of preparation method of Aripiprazole, comprising the following steps:
1- (2,3- dichlorophenyl) piperazine or its salt are dissolved in polar solvent, and Isosorbide-5-Nitrae-dibromobutane, acid binding agent is added, the
It is reacted under conditions of one heating, first is cooling, and the first filtering obtains the first filtrate；
First filtrate steams solvent, adds weak polar solvent crystallization, and the second filtering obtains the second filtrate, dry, obtains
1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt；
In absolute alcohol, 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt, 7- hydroxyl -3,4- dihydro quinoline promise is added
Ketone, alcohol alkali react under conditions of the second heating, and second is cooling, are poured into ice water and disperse, third filtering, washing, recrystallization,
Obtain Aripiprazole.
The preparation method of Aripiprazole provided by the present application, by Isosorbide-5-Nitrae-dibromobutane elder generation and 1- (2,3- dichlorophenyl) piperazine
Or its reactant salt, 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt intermediate is made, then by 1- (2,3- dichlorophenyl) piperazine
Aripiprazole is made in piperazine azepine cyclopentamine salt intermediate and the dihydro-quinolone condensation reaction of 7- hydroxyl -3,4-.It is provided by the present application
Preparation method, raw materials technology are easy to get, and route is brief, can get high-purity target product, with art methods ratio, optimize work
Skill condition, reduces production cost, good product quality, and high income is conducive to industrialized production.
1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt intermediate is shown below:
Specifically, preparing 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt intermediate first: by 1- (2,3- dichloros
Phenyl) piperazine or its salt is dissolved in polar solvent, acid binding agent is added, carries out under conditions of the first heating with Isosorbide-5-Nitrae-dibromobutane
Addition reaction, first cooling (preferably first is cooled to room temperature), is then filtered to remove inorganic salts through first, by the obtain first filter
Liquid steams solvent, adds weak polar solvent crystallization, and the second obtained filtrate drying is arrived 1- (2,3- bis- by the second filtering
Chlorphenyl) piperazine azepine cyclopentamine salt intermediate.Applicant has found in the course of the research, wraps in the loop coil intermediate being prepared
Containing 50% inorganic salts, if directly preparing Aripiprazole, gained finished product with 7- hydroxyl -3,4- dihydro-quinolone reaction without further purification
Impurity content is high.Therefore the application is by 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt intermediate of preparation through the first mistake
Filter, the operation that weak polar solvent crystallization, the second filtering is added, remove impurity, improve the purity of gained intermediate.And due to making
With safe and simple polar solvent system, the impurity (such as inorganic salts) for generating reaction is further reduced, and can obtain height
The intermediate ammonium salt of purity, chromatographic content > 99%.Wherein, the first filtrate steams the process of solvent, in practical operation, usually
Air-distillation retains trace solvent and material is avoided to solidify to without obviously distillating.Remaining polar solvent mostly can suitably reduce receipts
Rate, solvent evaporated will lead to the inconvenient subsequent crystallization operation of residue agglomeration.
Then again by 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt intermediate and 7- hydroxyl -3,4- dihydro-quinolone
Reaction.Applicant has found during studying reaction condition, due to the rigidity of loop coil, using in potassium carbonate/saleratus etc.
Under conditions of highly basic, intermediate cannot react at 80 DEG C；Temperature is increased to reacting at 120 DEG C, impurity is more.Therefore, this Shen
The problem of method that please be provided does alkali using stronger alcohol alkali, and moderate temperature reaction avoids darkening, and yield reduces.In addition,
If dissolvent residual limit needs strict control in final drug, or needs to increase in the reaction using two class solvents such as toluene or DMF
Finished product purification step, and the use of mixed solvent is unfavorable for continuous mass production to difficult solvent recovery.Therefore, the application selects
Use absolute alcohol as solvent.1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt intermediate and 7- hydroxyl -3,4- dihydro quinoline promise
Ketone reacts under conditions of the second heating, second cooling (preferably second is cooled to room temperature), is poured into dispersion in ice water and (is preferably poured into
0.1-1h is stirred in ice water), third filtering, washing obtain pale yellow powder, decolourize through recrystallization, obtain Aripiprazole, chromatography
Content > 99%.
Reaction equation of the invention is as follows:
The Aripiprazole of method provided by the invention, preparation is shown below:
Preferably, 1- (2, the 3- dichlorophenyl) piperazine or its salt be specially 1- (2,3- dichlorophenyl) piperazine, 1- (2,
3- dichlorophenyl) piperazine hydrochloride, 1- (2,3- dichlorophenyl) piperazine sulfate, 1- (2,3- dichlorophenyl) piperazine acetate,
Any one in 1- (2,3- dichlorophenyl) piperazine hydrobromide.
Preferably, the polar solvent is specially one of methanol, normal propyl alcohol, n-butanol, the tert-butyl alcohol or a variety of；With/
Or,
The volumetric usage of the polar solvent is 3-20 times of 1- (2,3- dichlorophenyl) piperazine or the quality of its salt.
The volumetric usage of the polar solvent is 3-20 times of 1- (2,3- dichlorophenyl) piperazine or the quality of its salt, is referred to
The dosage of polar solvent is 3-20 times of volume mass ratio of 1- (2,3- dichlorophenyl) piperazine or its hydrochloride, more preferable 5-10 times
Volume mass ratio.
Preferably, the acid binding agent is specially potassium carbonate, saleratus, sodium carbonate, sodium bicarbonate, pyridine, triethylamine, N,
Any one or more in N- diisopropylethylamine.
Preferably, the temperature of first heating is 40-80 DEG C；And/or the time of first heating is 6-15h.
Preferably, the weak polar solvent is specially petroleum ether, n-hexane, pentane, hexamethylene, benzene,toluene,xylene
One of or it is a variety of；And/or
The volumetric usage of the weak polar solvent is 1-10 times of 1- (2,3- dichlorophenyl) piperazine or the quality of its salt.
The volumetric usage of the weak polar solvent is 1-10 times of 1- (2,3- dichlorophenyl) piperazine or the quality of its salt, is
The dosage for referring to weak polar solvent is 1- (2,3- dichlorophenyl) piperazine or 1-10 times of volume mass ratio of its hydrochloride, preferably 2-5
Times volume mass ratio.
Preferably, the absolute alcohol is specially one of methanol, ethyl alcohol, normal propyl alcohol, isopropanol, n-butanol, the tert-butyl alcohol
Or it is a variety of.
Preferably, the alcohol alkali be specially potassium methoxide, it is potassium ethoxide, potassium isopropoxide, potassium tert-butoxide, sodium methoxide, sodium ethoxide, different
Any one or more in sodium propoxide, sodium tert-butoxide；And/or
The dosage of the alcohol alkali is the 1-4 times of equivalent of 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt.
In the application, the dosage of the preferably described alcohol alkali is 1-4 times of 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt
Equivalent, more preferable 1-2 times of equivalent.
Preferably, the temperature of second heating is 40-80 DEG C；And/or the time of first heating is 2-8h.
The selection of second heating temperature has relationship with the type of the reagent used, alkali especially used.Using weaker
Alkali, available Aripiprazole at 120 DEG C, but impure point is more, and reaction cannot obtain product at 80 DEG C.Therefore, the application
Stronger alkali (alcohol alkali is, it is preferable to use potassium alcoholate) is selected, at lower temperature (40-80 DEG C, preferably 70-80 DEG C, more preferable 70 DEG C)
Lower reaction obtains final product Aripiprazole.Preparation method provided by the present application, the product of readily available high-purity, uses letter
The solvent of single safety, help to obtain high quality/low impurity low solvent residue bulk pharmaceutical chemicals.
Preferably, it is recrystallized using alcohol-water mixed solution.
Alcohol used in the alcohol-water mixed solution, preferably methanol, ethyl alcohol, normal propyl alcohol, isopropanol, n-butanol, tertiary fourth
Any one or more in alcohol.Preferred alcohols solution concentration is 90--95%.It is preferable to use the ethyl alcohol of 90--95% concentration is water-soluble
Liquid.
1- (2, the 3- dichlorophenyl) piperazine hydrochloride that the present invention uses is provided by Suqian center pillar Pharmaceutical Technology Co., Ltd,
7- hydroxyl -3,4- dihydro-quinolone is provided by Jiaxing He Sheng biological products Co., Ltd, and potassium tert-butoxide is by Shandong West Asia chemistry work
Industry Co., Ltd provides, remaining raw material is that analysis is pure or chemical pure.
Embodiment 1
In 200ml anhydrous methanol, 1- (2,3- dichlorophenyl) piperazine hydrochloride 26.8g (0.1mol), Isosorbide-5-Nitrae-two are put into
Bromobutane 32.4g (0.15mol), potassium carbonate 27.7g (0.2mol) are stirred to react at 60 DEG C 12 hours, and first is cooling, is cooled to
Room temperature, the first filtering, appropriate anhydrous methanol wash filter cake, and merging filtrate is concentrated under reduced pressure into solid precipitation, is slowly added under stirring
100ml petroleum ether, is cooled to 20 degrees Celsius of crystallizations stirred below 1 hour, and the second filtering, appropriate petroleum ether is dry, receives
White fluffy powder 33.3g, i.e. 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt intermediate, HPLC content 99.5%, such as
Shown in Fig. 1.
The peak HPLC table is as shown in table 1 below:
Peak table
Detector A 255nm
| Peak number | Retention time | Area | Highly | Concentration | Concentration unit | Label |
| 1 | 7.259 | 2808 | 411 | 0.021 | M | |
| 2 | 10.184 | 839 | 74 | 0.006 | M | |
| 3 | 12.477 | 13114035 | 867468 | 99.497 | M | |
| 4 | 14.372 | 1317 | 102 | 0.010 | M | |
| 5 | 15.405 | 2640 | 176 | 0.020 | M | |
| 6 | 16.317 | 1096 | 62 | 0.008 | M | |
| 7 | 18.006 | 55909 | 3160 | 0.424 | M | |
| 8 | 34.576 | 1711 | 65 | 0.013 | M | |
| It amounts to | 13180355 | 871519 |
1HNMR (DMSO-d6,400MHz): 7.40 (d, 2H), 7.28 (t, 1H), 3.72 (t, 4H), 3.65 (t, 4H),
3.37 (m, 4H), 3.12 (m, 4H).(as shown in Figure 3)
Embodiment 2
In 200ml anhydrous normal butyl alcohol, 1- (2,3- dichlorophenyl) piperazine hydrochloride 26.8g (0.1mol), Isosorbide-5-Nitrae-are put into
Dibromobutane 32.4g (0.15mol), potassium carbonate 27.7g (0.2mol) are stirred to react at 60 DEG C 12 hours, and first is cooling, cooling
To room temperature, the first filtering, appropriate n-butanol washs filter cake, and merging filtrate is concentrated under reduced pressure into solid precipitation, is slowly added under stirring
100ml hexamethylene, is cooled to 20 degrees Celsius of crystallizations stirred below 1 hour, and the second filtering, appropriate petroleum ether is dry, receives
White fluffy powder 30.1g, i.e. 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt intermediate, HPLC content 99.3%.
Embodiment 3
In 100ml anhydrous tertiary butanol, 1- (2,3- dichlorophenyl) the piperazine ring butylamine salt 8.0g of the investment preparation of embodiment 1
(22mmol) and 7- hydroxyl -3,4- dihydro-quinolone 3.3g (20mmol) is warming up to 60 degrees Celsius, stirs lower investment by several times
4.5g potassium tert-butoxide, after finishing in 60 degrees Celsius insulation reaction 3 hours, second is cooling, is cooled to room temperature, is poured into 200ml ice water
In, it stirs 0.5 hour, third filtering.Filter cake is recrystallized with 95% ethanol water of 120ml, and active carbon decoloring is received white
Crystalline aripiprazole 7.1g, HPLC content 99.4%, as shown in Figure 2.
The peak HPLC table is as shown in table 2 below:
Peak table
Detector A 255nm
| Peak number | Retention time | Area | Highly | Concentration | Concentration unit | Label |
| 1 | 9.068 | 3380 | 478 | 0.032 | ||
| 2 | 13.065 | 9650 | 1065 | 0.091 | ||
| 3 | 14.115 | 12559 | 1736 | 0.119 | ||
| 4 | 17.883 | 11744 | 1624 | 0.111 | ||
| 5 | 23.850 | 12758 | 1778 | 0.130 | ||
| 6 | 28.226 | 10536351 | 692055 | 99.382 | ||
| 7 | 31.419 | 14452 | 1584 | 0.136 | ||
| It amounts to | 10601894 | 705287 |
1HNMR (CDCl3,400MHz): 8.85 (1H), 7.14~7.15 (m, 2H), 7.04 (d, 1H), 6.95 (dd, 1H),
6.54 (dd, 1H), 6.39 (d, 1H), 3.96 (t, 2H), 3.07 (m, 4H), 2.89 (t, 2H), 2.59~2.66 (m, 6H), 2.48
(t, 2H), 1.80 (m, 2H), 1.70 (m, 2H).(as shown in Figure 4)
The foregoing description of the disclosed embodiments enables those skilled in the art to implement or use the present invention.
Various modifications to these embodiments will be readily apparent to those skilled in the art, as defined herein
General Principle can be realized in other embodiments without departing from the spirit or scope of the present invention.Therefore, of the invention
It is not intended to be limited to the embodiments shown herein, and is to fit to and the principles and novel features disclosed herein phase one
The widest scope of cause.
Claims (10)
1. a kind of preparation method of Aripiprazole, which comprises the following steps:
1- (2,3- dichlorophenyl) piperazine or its salt are dissolved in polar solvent, and Isosorbide-5-Nitrae-dibromobutane, acid binding agent is added, and are added first
It is reacted under conditions of heat, first is cooling, and the first filtering obtains the first filtrate；
First filtrate steams solvent, adds weak polar solvent crystallization, and the second filtering obtains the second filtrate, dry, obtains 1-
(2,3- dichlorophenyl) piperazine azepine cyclopentamine salt；
In absolute alcohol, 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt, 7- hydroxyl -3,4- dihydro-quinolone, alcohol is added
Alkali reacts under conditions of the second heating, and second is cooling, is poured into ice water and disperses, third filtering, washing, recrystallization, obtain Ah
Vertical piperazine azoles.
2. preparation method according to claim 1, which is characterized in that 1- (2, the 3- dichlorophenyl) piperazine or its salt tool
Body is 1- (2,3- dichlorophenyl) piperazine, 1- (2,3- dichlorophenyl) piperazine hydrochloride, 1- (2,3- dichlorophenyl) piperazine sulfuric acid
Salt, 1- (2,3- dichlorophenyl) piperazine acetate, any one in 1- (2,3- dichlorophenyl) piperazine hydrobromide.
3. preparation method according to claim 1, which is characterized in that the polar solvent is specially methanol, normal propyl alcohol, just
One of butanol, tert-butyl alcohol are a variety of；And/or
The volumetric usage of the polar solvent is 3-20 times of 1- (2,3- dichlorophenyl) piperazine or the quality of its salt.
4. preparation method according to claim 1, which is characterized in that the acid binding agent be specially potassium carbonate, saleratus,
Sodium carbonate, sodium bicarbonate, pyridine, triethylamine, N, any one or more in N- diisopropylethylamine.
5. preparation method according to claim 1, which is characterized in that the temperature of first heating is 40-80 DEG C；With/
Or, the time of first heating is 6-15h.
6. preparation method according to claim 1, which is characterized in that the weak polar solvent be specially petroleum ether, just oneself
One of alkane, pentane, hexamethylene, benzene,toluene,xylene are a variety of；And/or
The volumetric usage of the weak polar solvent is 1-10 times of 1- (2,3- dichlorophenyl) piperazine or the quality of its salt.
7. preparation method according to claim 1, which is characterized in that the absolute alcohol is specially methanol, ethyl alcohol, positive third
Alcohol, isopropanol, one of n-butanol, tert-butyl alcohol or a variety of.
8. preparation method according to claim 1, which is characterized in that the alcohol alkali is specially potassium methoxide, potassium ethoxide, isopropyl
Potassium alcoholate, potassium tert-butoxide, sodium methoxide, sodium ethoxide, sodium isopropylate, any one or more in sodium tert-butoxide；And/or
The dosage of the alcohol alkali is the 1-4 times of equivalent of 1- (2,3- dichlorophenyl) piperazine azepine cyclopentamine salt.
9. preparation method according to claim 1, which is characterized in that the temperature of second heating is 40-80 DEG C；With/
Or, the time of first heating is 2-8h.
10. preparation method according to claim 1, which is characterized in that recrystallized using alcohol-water mixed solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910498357.XA CN110128336A (en) | 2019-06-10 | 2019-06-10 | A kind of preparation method of Aripiprazole |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910498357.XA CN110128336A (en) | 2019-06-10 | 2019-06-10 | A kind of preparation method of Aripiprazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110128336A true CN110128336A (en) | 2019-08-16 |
Family
ID=67580916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910498357.XA Pending CN110128336A (en) | 2019-06-10 | 2019-06-10 | A kind of preparation method of Aripiprazole |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110128336A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1784385A (en) * | 2003-05-08 | 2006-06-07 | 德尔马化学有限公司 | Process for the preparation of carbostyril derivatives, such as aripiprazole and its intermediates |
| CN102898428A (en) * | 2012-09-20 | 2013-01-30 | 常州大学 | Microwave synthesis method of spirocyclopiperazinium compound |
| US20180155290A1 (en) * | 2015-05-08 | 2018-06-07 | Davuluri Ramamohan Rao | Improved Process for the Preparation of Aripiprazole with Reduced Particle Size |
-
2019
- 2019-06-10 CN CN201910498357.XA patent/CN110128336A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1784385A (en) * | 2003-05-08 | 2006-06-07 | 德尔马化学有限公司 | Process for the preparation of carbostyril derivatives, such as aripiprazole and its intermediates |
| CN102898428A (en) * | 2012-09-20 | 2013-01-30 | 常州大学 | Microwave synthesis method of spirocyclopiperazinium compound |
| US20180155290A1 (en) * | 2015-05-08 | 2018-06-07 | Davuluri Ramamohan Rao | Improved Process for the Preparation of Aripiprazole with Reduced Particle Size |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104610250B (en) | 1,2,3-thiadiazole-5-formamidine compound containing three N-heterocycles and synthesis | |
| CN104250232A (en) | Preparation method of parecoxib sodium | |
| CN103664561B (en) | The preparation method of a kind of metconazole and intermediate thereof | |
| CN106565627B (en) | Preparation method of febuxostat medicinal crystal form | |
| CN108047055B (en) | Method for synthesizing deuterated methylamine salt by using halogenated deuterated methane | |
| EP1873151B1 (en) | Improved process for producing moxonidine | |
| CN105330598A (en) | Preparing method for pirfenidone | |
| US10017472B2 (en) | Hydrate of 2-isopropoxy-5-methyl-4-(piperidin-4-yl) aniline dihydrochloride, preparation method and use of the same | |
| EP2669293B1 (en) | Preparation method of rocuronium | |
| CN106279175A (en) | A kind of preparation method of Ertapenem Sodium | |
| CN107226777A (en) | A kind of synthetic method of 1,2 biphenoxyl ethane temperature-sensitive sensitizers | |
| CN103923087B (en) | A kind of preparation method of deuterium-labeled sitagliptin | |
| CN110128336A (en) | A kind of preparation method of Aripiprazole | |
| CN109053585B (en) | Synthetic method of triclabendazole | |
| CN109761910B (en) | Synthetic method of ideprop | |
| CN107915694A (en) | 1 [2 (2,4 3,5-dimethylphenyl sulfydryl) phenyl] piperazine hydrochloride and preparation method thereof | |
| CN102731474B (en) | Preparation method of imatinib | |
| CN105566429B (en) | Preparation method of obeticholic acid type 1 | |
| CN104098509A (en) | Method for preparing A type atazanavir sulfate | |
| CN110117251B (en) | Preparation method of 4, 5-dichloro-2-hydroxypyridine | |
| CN104829514B (en) | A kind of synthetic method of pharmaceutical intermediate | |
| CN115368317A (en) | Improved method for preparing aripiprazole intermediate | |
| CN103408542A (en) | Preparation method of high-purity anhydrous dasatinib | |
| CN103073498A (en) | Novel preparation method for (R)-Alpha-amino-e-caprolactam | |
| CN112010810B (en) | Method for preparing high-purity rilpivirine intermediate by one-pot method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190816 |
|
| RJ01 | Rejection of invention patent application after publication |